The far-flung tumors of tuberous sclerosis complex, noncancerous but hardly benign, are shedding light on how malignancies develop.
The Price of Personalization
Tailoring treatments, patient by patient, can achieve remarkable results. But can we afford to make every disease rare?
Our Dark Matter
Genes account for less than 2% of the human genome—and much of what determines health and disease may lie elsewhere.